South San Francisco, CA, United States of America

Paroma Chakravarty

USPTO Granted Patents = 7 (Patent Applications = 4)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 6.1

ph-index = 2

Forward Citations = 13(Granted Patents)

Location History:

South San Francisco, CA (US) (2016 - 2023)
San Francisco, CA (US) (2021 - 2023)

Company Filing History:

Hoffmann-la Roche Inc.

patents

where one patent can have more than one assignee

Years Active: 2016-2025

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12410189 - Polymorphs and solid forms of (S)-2-2((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9- yl)amino)propanamide, and methods of production (2025-09-09),

2. 11780834 - Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3- yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use (2023-10-10),

3. 11591345 - Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production (2023-02-28),

4. 11028100 - Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production (2021-06-08),

5. 10954234 - Solid forms of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use (2021-03-23),

6. 9505725 - Crystalline and mesomorphous forms of an AKT inhibiting pyrimidinyl-cyclopentane compound, compositions and methods thereof (2016-11-29),

7. 9290458 - Amorphous form of an AKT inhibiting pyrimidinyl-cyclopentane compound, compositions and methods thereof (2016-03-22),

Title: Paroma Chakravarty - Innovator in Pharmaceutical Patents

Introduction

Paroma Chakravarty is a notable inventor based in South San Francisco, California. With an impressive portfolio of six patents, she has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative compounds for cancer treatment.

Latest Patents

Chakravarty's most recent patents include groundbreaking work on solid forms of the compound 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol. This invention encompasses processes for preparing fused tricyclic compounds containing substituted phenyl or pyridinyl moieties, aimed at treating cancer. Another key patent focuses on crystalline polymorph forms of (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide (GDC-0077), detailing methods of production and applications of these solid forms in medicinal use.

Career Highlights

Paroma has had an impactful career, having worked with esteemed companies in the pharmaceutical industry, including Genentech, Inc. and Hoffmann-La Roche Inc. Her expertise in drug formulation and development has paved the way for advancements in cancer therapeutics, making her a vital contributor to the scientific community.

Collaborations

Throughout her career, Chakravarty has collaborated with numerous professionals in her field. Notable coworkers include Francis Gosselin and Karthik Nagapudi, with whom she has shared her innovative ideas and combined expertise to further advance pharmaceutical research.

Conclusion

Paroma Chakravarty exemplifies a dedicated inventor in the pharmaceutical sector. Her continuous innovation and successful patents not only highlight her skills but also contribute to the greater good by improving treatment options for cancer patients. Her commitment to research and collaboration signifies the vital intersection of science, invention, and healthcare.

This text is generated by artificial intelligence and may not be accurate.